Constitutive activity of GPR40/FFA1. Intrinsic or assay dependent?

Methods in Enzymology

Volumn 484, Issue C, 2010, Pages 569-590

  Stoddart, Leigh A ^a   Milligan, Graeme ^b  

^a UNIVERSITY OF NOTTINGHAM   (United Kingdom)

^b UNIVERSITY OF GLASGOW   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; BLASTICIDIN; BLOCKING AGENT; BOVINE SERUM ALBUMIN; CALCIUM ION; DOXYCYCLINE; FATTY ACID; G PROTEIN COUPLED RECEPTOR 40; GSK 250089 A; GUANINE NUCLEOTIDE BINDING PROTEIN; GUANOSINE 5' O (3 THIOTRIPHOSPHATE); HYGROMYCIN; INOSITOL PHOSPHATE; LINOLENIC ACID; P 6407; P 8761; PALMITIC ACID; PENICILLIN G; POLOXAMER; POLY DEXTRO LYSINE; PROBENECID; ROSIGLITAZONE; STREPTOMYCIN; TROGLITAZONE; UNCLASSIFIED DRUG; YM 254890; ZEOCIN;

ALUMINUM FOIL; BINDING ASSAY; BOOK; CALCIUM CELL LEVEL; CALCIUM MOBILIZATION; CELL MEMBRANE; CELL STRAIN HEK293; CONCENTRATION RESPONSE; DRUG TARGETING; HUMAN; IMMUNOPRECIPITATION; LIQUID SCINTILLATION COUNTING; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION;

EID: 78049259128     PISSN: 00766879     EISSN: None     Source Type: Book Series    
DOI: 10.1016/B978-0-12-381298-8.00028-9     Document Type: Chapter

References (46)

1. o1 by the ghrelin receptor. Mol. Pharmacol. 2009, 76(4):802-811.
2. Bond R.A., Ijzerman A.P. Recent developments in constitutive receptor activity and inverse agonism, and their potential for GPCR drug discovery. Trends Pharmacol. Sci. 2006, 27(2):92-96.
3. Briscoe C.P., Tadayyon M., Andrews J.L., Benson W.G., Chambers J.K., Eilert M.M., Ellis C., Elshourbagy N.A., Goetz A.S., Minnick D.T., Murdock P.R., Sauls H.R., et al. The orphan G protein-coupled receptor GPR40 is activated by medium and long chain fatty acids. J. Biol. Chem. 2003, 278(13):11303-11311.
4. Briscoe C.P., Peat A.J., McKeown S.C., Corbett D.F., Goetz A.S., Littleton T.R., McCoy D.C., Kenakin T.P., Andrews J.L., Ammala C., Fornwald J.A., Ignar D.M., et al. Pharmacological regulation of insulin secretion in MIN6 cells through the fatty acid receptor GPR40: Identification of agonist and antagonist small molecules. Br. J. Pharmacol. 2006, 148(5):619-628.
5. Brown A.J., Goldsworthy S.M., Barnes A.A., Eilert M.M., Tcheang L., Daniels D., Muir A.I., Wigglesworth M.J., Kinghorn I., Fraser N.J., Pike N.B., Strum J.C., et al. The orphan G protein-coupled receptors GPR41 and GPR43 are activated by propionate and other short chain carboxylic acids. J. Biol. Chem. 2003, 278(13):11312-11319.
6. Canals M., Milligan G. Constitutive activity of the cannabinoid CB1 receptor regulates the function of co-expressed mu opioid receptors. J. Biol. Chem. 2008, 283(17):11424-11434.
7. Chen A., Gao Z.G., Barak D., Liang B.T., Jacobson K.A. Constitutive activation of A(3) adenosine receptors by site-directed mutagenesis. Biochem. Biophys. Res. Commun. 2001, 284(3):596-601.
8. Edfalk S., Steneberg P., Edlund H. Gpr40 is expressed in enteroendocrine cells and mediates free fatty acid stimulation of incretin secretion. Diabetes 2008, 57(9):2280-2287.
9. Ellis J., Pediani J.D., Canals M., Milasta S., Milligan G. Orexin-1 receptor-cannabinoid CB1 receptor heterodimerization results in both ligand-dependent and -independent coordinated alterations of receptor localization and function. J. Biol. Chem. 2006, 281(50):38812-38824.
10. Feng D.D., Luo Z.Q., Roh S.G., Hernandez M., Tawadros N., Keating D.J., Chen C. Reduction in voltage-gated K+currents in primary cultured rat pancreatic beta-cells by linoleic acids. Endocrinology 2006, 147(2):674-682.
11. Flodgren E., Olde B., Meidute-Abaraviciene S., Winzell M.S., Ahren B., Salehi A. GPR40 is expressed in glucagon producing cells and affects glucagon secretion. Biochem. Biophys. Res. Commun. 2007, 354(1):240-245.
12. Fujiwara K., Maekawa F., Yada T. Oleic acid interacts with GPR40 to induce Ca2+ signaling in rat islet beta-cells: Mediation by PLC and L-type Ca2+ channel and link to insulin release. Am. J. Physiol. Endocrinol. Metab. 2005, 289(4):E670-E677.
13. Hall D.A., Strange P.G. Evidence that antipsychotic drugs are inverse agonists at D-2 dopamine receptors. Br. J. Pharmacol. 1997, 121(4):731-736.
14. Hardy S., St-Onge G.G., Joly E., Langelier Y., Prentki M. Oleate promotes the proliferation of breast cancer cells via the G protein-coupled receptor GPR40. J. Biol. Chem. 2005, 280(14):13285-13291.
15. Hein P., Goepel M., Cotecchia S., Michel M.C. A quantitative analysis of antagonism and inverse agonism at wild-type and constitutively active hamster alpha(1B)-adrenoceptors. Naunyn Schmiedebergs Arch. Pharmacol. 2001, 363(1):34-39.
16. Holst B., Cygankiewicz A., Jensen T.H., Ankersen M., Schwartz T.W. High constitutive signaling of the ghrelin receptor: Identification of a potent inverse agonist. Mol. Endocrinol. 2003, 17(11):2201-2210.
17. Hu H., He L.Y., Gong Z., Li N., Lu Y.N., Zhai Q.W., Liu H., Jiang H.L., Zhu W.L., Wang H.Y. A novel class of antagonists for the FFAs receptor GPR40. Biochem. Biophys. Res. Commun. 2009, 390(3):557-563.
18. Itoh Y., Kawamata Y., Harada M., Kobayashi M., Fujii R., Fukusumi S., Ogi K., Hosoya M., Tanaka Y., Uejima H., Tanaka H., Maruyama M., et al. Free fatty acids regulate insulin secretion from pancreatic beta cells through GPR40. Nature 2003, 422(6928):173-176.
19. Kebede M., Alquier T., Latour M.G., Semache M., Tremblay C., Poitout V. The fatty acid receptor GPR40 plays a role in insulin secretion in vivo after high-fat feeding. Diabetes 2008, 57(9):2432-2437.
20. Kenakin T. Inverse, protean, and ligand-selective agonism: Matters of receptor conformation. FASEB J. 2001, 15(3):598-611.
21. Kotarsky K., Nilsson N.E., Flodgren E., Owman C., Olde B. A human cell surface receptor activated by free fatty acids and thiazolidinedione drugs. Biochem. Biophys. Res. Commun. 2003, 301(2):406-410.
22. Lan H., Hoos L.M., Liu L., Tetzloffl G., Hu W.W., Abbondanzo S.J., Vassileva G., Gustafson E.L., Hedrick J.A., Davis H.R. Lack of FFAR1/GPR40 does not protect mice from high-fat diet-induced metabolic disease. Diabetes 2008, 57(11):2999-3006.
23. Latour M.G., Alquier T., Oseid E., Tremblay C., Jetton T.L., Luo J., Lin D.C.H., Poitout V. GPR40 is necessary but not sufficient for fatty acid stimulation of insulin secretion in vivo. Diabetes 2007, 56(4):1087-1094.
24. Le Poul E., Loison C., Struyf S., Springael J.Y., Lannoy V., Decobecq M.E., Brezillon S., Dupriez V., Vassart G., Van Damme J., Parmentier M., Detheux M. Functional characterization of human receptors for short chain fatty acids and their role in polymorphonuclear cell activation. J. Biol. Chem. 2003, 278(28):25481-25489.
25. Lee P.H. Label-free optical biosensor: a tool for G protein-coupled receptors pharmacology profiling and inverse agonists identification. J. Recept. Signal Transduct. Res. 2009, 29(3-4):146-153.
26. Lopez-Gimenez J.F., Vilaro M.T., Milligan G. Morphine desensitization, internalization, and down-regulation of the mu opioid receptor is facilitated by serotonin 5-hydroxytryptamine(2A) receptor coactivation. Mol. Pharmacol. 2008, 74(5):1278-1291.
27. May L.T., Briddon S.J., Hill S.J. Antagonist selective modulation of adenosine A(1) and A(3) receptor pharmacology by the food dye Brilliant Black BN: Evidence for allosteric interactions. Mol. Pharmacol. 2010, 77(4):678-686.
28. Milligan G. Constitutive activity and inverse agonists of G protein-coupled receptors: A current perspective. Mol. Pharmacol. 2003, 64(6):1271-1276.
29. 35 S]GTPγS binding assays. Trends Pharmacol. Sci. 2003, 24:87-90.
30. Milligan G., Feng G.-J., Ward R.J., Sartania N., Ramsay D., McLean A.J., Carrillo J.J. G protein-coupled receptor fusion proteins in drug discovery. Curr. Pharm. Des. 2004, 10:1989-2001.
31. Milligan G., Parenty G., Stoddart L.A., Lane J.R. Novel pharmacological applications of G-protein-coupled receptor-G protein fusions. Curr. Opin. Pharmacol. 2007, 7:521-526.
32. Mitchell F.M., Buckley N.J., Milligan G. Enhanced degradation of the phosphoinositidase c-linked guanine-nucleotide-binding protein g(q)alpha g(11)alpha following activation of the human m1-muscarinic acetylcholine-receptor expressed in Cho cells. Biochem. J. 1993, 293:495-499.
33. Nolan C.J., Madiraju M.S.R., Delghingaro-Augusto V., Peyot M.L., Prentki M. Fatty acid signaling in the beta-cell and insulin secretion. Diabetes 2006, 55:S16-S23.
34. Rocheville M., Jerman J.C. 7TM pharmacology measured by label-free: A holistic approach to cell signalling. Curr. Opin. Pharmacol. 2009, 9(5):643-649.
35. Salehi A., Flodgren E., Nilsson N.E., Jimenez-Feltstrom J., Miyazaki J., Owman C., Olde B. Free fatty acid receptor 1 (FFA(1)R/GPR40) and its involvement in fatty-acid-stimulated insulin secretion. Cell Tissue Res. 2005, 322(2):207-215.
36. Schnell S., Schaefer M., Schofl C. Free fatty acids increase cytosolic free calcium and stimulate insulin secretion from beta-cells through activation of GPR40. Mol. Cell. Endocrinol. 2007, 263(1-2):173-180.
37. Shapiro H., Shachar S., Sekler I., Hershfinkel M., Walker M.D. Role of GPR40 in fatty acid action on the beta cell line INS-1E. Biochem. Biophys. Res. Commun. 2005, 335(1):97-104.
38. Smith N.J., Stoddart L.A., Devine N.M., Jenkins L., Milligan G. The action and mode of binding of thiazolidinedione ligands at Free Fatty Acid receptor 1. J. Biol. Chem. 2009, 284(26):17527-17539.
39. Steneberg R., Rubins N., Bartoov-Shifman R., Walker M.D., Edlund H. The FFA receptor GPR40 links hyperinsulinemia, hepatic steatosis, and impaired glucose homeostasis in mouse. Cell Metab. 2005, 1(4):245-258.
40. Stoddart L.A., Brown A.J., Milligan G. Uncovering the pharmacology of the G protein-coupled receptor GPR40: High apparent constitutive activity in guanosine 5'-O-(3-[S-35] thio) triphosphate binding studies reflects binding of an endogenous agonist. Mol. Pharmacol. 2007, 71(4):994-1005.
41. Stoddart L.A., Smith N.J., Jenkins L., Brown A.J., Milligan G. Conserved polar residues in transmembrane domains V, VI, and VII of free fatty acid receptor 2 and free fatty acid receptor 3 are required for the binding and function of short chain fatty acids. J. Biol. Chem. 2008, 283(47):32913-32924.
42. Stoddart L.A., Smith N.J., Milligan G. International union of pharmacology. LXXI. Free fatty acid receptors FFA1,-2, and-3: Pharmacology and pathophysiological functions. Pharmacol. Rev. 2008, 60(4):405-417.
43. Tan C.P., Feng Y., Zhou Y.P., Eiermann G.J., Petrov A., Zhou C.Y., Lin S.N., Salituro G., Meinke P., Mosley R., Akiyama T.E., Einstein M., et al. Selective small-molecule agonists of G protein-coupled receptor 40 promote glucose-dependent insulin secretion and reduce blood glucose in mice. Diabetes 2008, 57(8):2211-2219.
44. Tomita T., Masuzaki H., Noguchi M., Iwakura H., Fujikura J., Tanaka T., Ebihara K., Kawamura J., Komoto I., Kawaguchi Y., Fujimoto K., Doi R., et al. GPR40 gene expression in human pancreas and insulinoma. Biochem. Biophys. Res. Commun. 2005, 338(4):1788-1790.
45. TM system to regulate GPCR expression. Methods in Molecular Biology 2010, Humana Press. 3rd edn. G. Willars, J.A. Challiss (Eds.).
46. Yonezawa T., Katoh K., Obara Y. Existence of GPR40 functioning in a human breast cancer cell line, MCF-7. Biochem. Biophys. Res. Commun. 2004, 314(3):805-809.